Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Rectal Cancer: early-phase trial registry
32 of 72 indexed Rectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 32 currently recruiting · #191 of 28,707 conditions by registered trial count
Rectal Cancer: 72 US clinical trials tracked, 32 recruiting.
Rectal Cancer is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition rectal-cancer
OPEN 32 | RECR 44% | LATE 4 | EARLY 31 | RANK #191 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Rectal Cancer lists 32 open slots (44% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Rectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Rectal Cancer is recruiting above its size-band peers.
32 of 72 indexed trials (44.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Rectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 8 of 72 trials (11.1%). 48 distinct sponsors appear on at least one study for this condition label.
-
Most Rectal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 71 trials that report a genuine target (sentinel values excluded). 44 of those (62%) plan for fewer than 100 participants.
-
Rectal Cancer research is mostly interventional.
58 interventional and 14 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 1 of 2
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Washington University School of Medicine
NCT06340646
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT07227636
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Canadian Cancer Trials Group
NCT06205485
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Colospan
NCT04184973
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
University of Nebraska
NCT05254327
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03190941
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
Washington University School of Medicine
NCT04339374
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
Massachusetts General Hospital
NCT05914766
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations
NCT07011576
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
Virginia Commonwealth University
NCT04643366
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
H. Lee Moffitt Cancer Center and Research Institute
NCT06337552
Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population
Bassett Healthcare
NCT04245683
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
NCT05806931
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Washington University School of Medicine
NCT03516708
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
University of Colorado, Denver
NCT07292298
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Weill Medical College of Cornell University
NCT05024097
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Dana-Farber Cancer Institute
NCT06565052
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT05672524
Exosomes in Rectal Cancer
University of Kansas Medical Center
NCT03874559
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
Henry Ford Health System
NCT05526079
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
University of South Florida
NCT06380101
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT06637462
Ultra-fractionated Radiotherapy for Rectal Cancer
University of Texas Southwestern Medical Center
NCT04677413
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
Weill Medical College of Cornell University
NCT05943210
F-Tryptophan PET/CT in Human Cancers
Barbara Ann Karmanos Cancer Institute
NCT05556473
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
Genomic Structural Variation in Cancer Susceptibility
Memorial Sloan Kettering Cancer Center
NCT00996710
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
University Medical Center Groningen
NCT01558921
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Memorial Sloan Kettering Cancer Center
NCT02008656
Supportive Oncology Care At Home RCT
Massachusetts General Hospital
NCT04544046
CRC Detection Reliable Assessment With Blood
New Day Diagnostics
NCT05551052
Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations
M.D. Anderson Cancer Center
NCT00648635
RCT of Mobile Apps & FitBit v. Usual Care
Weill Medical College of Cornell University
NCT03623464
Multicenter Phase II Study of Transanal TME (taTME)
Icahn School of Medicine at Mount Sinai
NCT03144765
The Exercise And Colorectal Cancer Treatment Trial
Pennington Biomedical Research Center
NCT03975491
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
NCT04963283
Microbiome and Rectal Cancer
University of South Florida
NCT04223102
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Case Comprehensive Cancer Center
NCT03283540
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT02403505
Organ Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
NCT03548961
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06710847
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
University Hospitals Cleveland Medical Center
NCT00622557
Adherence to Colon Cancer Screening (ACCS)
Ohio State University Comprehensive Cancer Center
NCT02112747
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 19 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Rectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Rectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Rectal Cancer page
72 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 32 Rectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Rectal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rectal Cancer condition card totals 72 registered trials; most-linked intervention Leucovorin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.